Zhejiang Jiuzhou Pharmaceutical Co., Ltd completed the acquisition of Ruihua Pharmaceutical Co., Ltd. from Sandoz Pharmaceutical Co., Ltd.
April 31, 2023
Share
Zhejiang Jiuzhou Pharmaceutical Co., Ltd entered into Sale and Purchase Agreement to acquire Ruihua (Zhongshan) Pharmaceutical Co., Ltd. from Sandoz (China) Pharmaceutical Co., Ltd. for $15.1 million on September 26, 2022. The transaction is expected to close in the beginning of 2023. Transaction has been approved in the 27th Meeting of the Company's 7th Directorate held on March 12, 2023, and is subject to the Shareholders' Approval. As of March 29, 2023, The shareholders of Zhejiang Jiuzhou Pharmaceutical has approved the deal.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd completed the acquisition of Ruihua (Zhongshan) Pharmaceutical Co., Ltd. from Sandoz (China) Pharmaceutical Co., Ltd. on April 1, 2023.
Zhejiang Jiuzhou Pharmaceutical Co Ltd is a China-based company mainly engaged in the production, sales and service of chemical raw materials and intermediates. The Company is committed to providing one-stop customized pharmaceutical contract development and manufacturing organization (CDMO) services to global pharmaceutical companies, biotechnology companies, scientific research institutions, and others, including small molecule chemical drugs, peptide drugs, conjugated drugs and small nucleic acid drugs. The CDMO projects served by the Company involve therapeutic areas such as anti-tumor, anti-heart failure, anti-depression, treatment of Parkinson's disease, anti-lung cancer, anti-virus, anti-diabetes, and anti-respiratory system infection.
ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD 
